Please assess the completion status of the following clinical trial:

Trial Title: S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically diagnosed primary systemic amyloidosis based on the following:~  * Deposition of fibrillary protein with Congo red positive stain or characteristic electron microscopic appearance~ * Monoclonal light chain protein (Bence-Jones protein) in serum or urine or immunohistochemical studies~ * Evidence of tissue involvement other than carpal tunnel syndrome~ * Diagnostic histologic material available for central pathology review~    * Confirmation of tissue diagnosis at all sites of organ dysfunction encouraged~* No senile, secondary, localized, dialysis-related, or familial amyloidosis~* No known therapy-related myelodysplasia~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* SWOG 0-4~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Cardiovascular:~* No NYHA class IV status~Other:~* No uncontrolled diabetes~* No active peptic ulcer disease~* No medical condition that precludes high-dose steroids~* No second malignancy within 5 years except:~* Adequately treated nonmelanomatous skin cancer~* In situ cervical cancer~* Adequately treated stage I/II cancer in complete remission~* Not pregnant or nursing~* Effective contraception required of fertile patients~* Blood/body fluid analyses within 14 days prior to registration~* Imaging/exams for tumor measurement within 28 days prior to registration~* Other screening exams within 42 days prior to registration~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon alfa~Chemotherapy~* Prior melphalan allowed, but recovered from effects~* At least 4 weeks since cytotoxic therapy and recovered~Endocrine therapy~* Prior prednisone allowed, but recovered from effects~* At least 4 weeks since prior glucocorticoids~* No prior dexamethasone~* No planned or concurrent dexamethasone or other therapy for primary systemic amyloidosis~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- induction and maintenance (Type: EXPERIMENTAL): dexamethasone induction followed by alpha interferon maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).